Alpha 1 Acid Glycoprotein

Athens Research

Alpha 1 Acid Glycoprotein

9

Protein Glycosylation studies, In Vitro Diagnostics, Antisera Production

Research Use Only

≥95% by SDS-PAGE

Alpha-1-acid glycoprotein 1

Alpha-1 acid glycoprotein (AGP), a glycoprotein constituting 55–140 mg/dL of plasma, features five N-linked glycan chains comprising 40–45% of its mass, including sialylated bi-/tri-/tetra-antennary structures critical for ligand interactions. Thus contributing to its use as a standard for glycosylation studies. As a major acute-phase reactant, AGP surges up to 5-fold during inflammation, synergizing with haptoglobin to diagnose acute inflammation and differentiate hepatic vs. obstructive jaundice. Its glycosylation profile shifts in pathologies: acute inflammation increases bi-antennary and alfa1,3-fucosylated glycans, while chronic states enhance tri-/tetra-antennary fucosylation. AGP binds progesterone 15x more avidly than albumin and complexes with vitamin B-12 when sialic acid-deficient, influencing drug pharmacokinetics and nutrient transport. AGP modulates immunity via TLR-2/4 interactions, exacerbating TLR-2-mediated sepsis mortality while inhibiting LPS-driven NETosis. Dysregulated AGP correlates with rheumatoid arthritis, Waldenström macroglobulinemia, and metastatic cancers, where glycoforms alter platelet aggregation and neutrophil adhesion. The AGP:haptoglobin ratio aids in diagnosing bone marrow disorders and hemolytic anemia, reflecting erythropoietic activityTherapeutically, AGP’s drug-binding capacity informs personalized dosing for basic drugs (e.g., chlorpromazine), while engineered glycoforms are explored for targeted anti-inflammatory therapies.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -20°C

41116100